Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-05-01
2009-11-10
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
07615576
ABSTRACT:
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
REFERENCES:
patent: 5441951 (1995-08-01), Serhan
patent: 6387953 (2002-05-01), Serhan
patent: 6433202 (2002-08-01), Serhan
patent: 6659282 (2003-12-01), Serhan
patent: 6703423 (2004-03-01), Serhan
patent: 6710084 (2004-03-01), Serhan
patent: 6720354 (2004-04-01), Serhan
patent: 6864288 (2005-03-01), Serhan
patent: 6927238 (2005-08-01), Serhan
patent: 6960674 (2005-11-01), Serhan
patent: 7132451 (2006-11-01), Serhan
patent: 7227031 (2007-06-01), Serhan
patent: 2003/0191332 (2003-10-01), Serhan
patent: WO 98/11049 (1998-03-01), None
patent: WO 00/54761 (2000-09-01), None
patent: WO 03/039533 (2003-05-01), None
U.S. Appl. No. 11/531,921; U.S. Appl. No. 11/837,964.
Takano, T., Clish, C.B., Gronert, K., Petasis, N. & Serhan, C.N., J C/in. Invest. 101, pp. 819-826.
Olsen et al., Chemistry and Physic of Lipids, vol. 80, pp. 3-19, 1996.
Grant, S.M. & Goa K.L. (1992) Drugs 43, 899-924.
Weissmann, G.,Sci. Am. 264, 1991, pp. 84-90.
Ridker, P.M., Cushman, M., Stamp, M.J., Tracy, T.P. & Hennekens, C.H.,N. Engl. J. Med., 336, pp. 973-979, 1997.
Marcus, A.J.,N. Engl. J. Med. 333, pp. 656-658, 1995.
Herschman, H.RR.,Trends Cardiovasc. Med. 8, pp. 145-150, 1998.
Serhan, C.N.,Prostaglandins53, 1997, pp. 107-137, 1997.
Chiang, N., Takano., T., Clish C.B., Petasis, N.A., Tai, H.H. & Serhan, C.N.,J. Pharm. Exp. Ther. 287, pp. 779-790, 1998.
Lee, T.H., Crea, A.E., Grant, V., Spur, B.W., Marron, B.E., Nicolaou, K.C., Reardon, E., Brezinski, M. & Serhan, C.N.,Amer. Rev. Respir. Dis. 141, pp. 1453-1458, 1990.
Chavis, C., Chanez, P., Vachier, I. Bousquet, J., Michel, F. B., & Godard, P.,Biochem. Biophys, Res. Commun. 207, pp. 121-124, 1995.
Thomas, E., Leroux, J.L., Blotman, F. Chavis, C.,Inflamm. Res., 44, pp. 121-124, 1995.
Gewirtz, A.T., McMormick, B., Neish, A.S., Petasis, N.A., Gronert, K., Serhan, C.N. & Madara, J.L.,J. Clin. Invest. 101, pp. 1860-1869, 1998.
Pillinger, M.H. & Abramson, S.B.,Rheum. Dis. Clin North Am. 21, pp. 691-714, 1995.
Hagihara, H., Nomoto, A., Mutoh, S., Yamaguchi, I., & Ono, T.,Atherosclerosis91, pp. 107-116, 1991.
McLaughlan, J. M., Beth R., Vautier, G., Robins, R.A., Scott, B. B., Hawkey, C.J. & Jenkins, D.,J. Pathol. 181, pp. 87-92, 1997.
Anezaki, K., Asakura, H., Homma, T., Ishizuka, K., Funakoshi, K., Tsukada, Y. & Narisawa, R.,Intern. Med. 37, 253-258, 1998.
Iverson, L. & Kragballe, K.,Skin Immune System(SIS), Ed. Bos, J.D. (CRC Press, Boca Raton), 1997, pp. 227-237.
Ensor, C. M. & Tai, H.-H.,Prostaglandins, Leukotrienes, Lipoxins, and PAF, ed. Bailey, J.M. (Plenum Press, New York), 1991, pp. 39-52.
Serhan, C.N., Fiore, S., Brezinski, D.A. & Lynch, S.,Biochemistry32, pp. 6313-6319, 1993.
Maddox, J.F., Colgan, S.P., Clish, C.B., Petasis, N.A., Fokin, V.V. & Serhan, C.N.,FASEB J., 12, pp. 487-494, 1998.
Serhan, C.N., Maddox, J.F., Petasis, N.A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H.R., Colgan, S.P. & Madara, J.L.,Biochemistry34, pp. 14609-14615, 1995.
Takano, T., Clish, C.B., Gronert, K., Petasis, N. & Serhan, C.N.,J Clin. Invest. 101, pp. 819-826, 1998.
Sin, Y.M., Sedgwick, A.D., Chea, E.P. & Willoughby, D.A.,Ann. Rheum. Dis. 45, pp. 873-877.
Bradley, P.P., Priebat, D.A., Christensen, R.D., & Rothstein, G.,J. Invest. Dermatol. 78, pp. 206-209, 1982.
Edwards, J.C.W., Sedgwick, A.D. & Willoughby, D.A.,J. Pathol. 134, 1981, pp. 147-156.
Tessier, P.A., Naccache, P.H., Clark-Lewis, I., Gladue, R.P., Neote, K.S., & McColl, S.R.,J. Immunol. 159, 1997, pp. 3593-3602.
Dahlen, S.E. & Serhan, C.N. inLipoxygenases and Their Products, eds. Crooke, S.T. & Wong, A. (Academic Press, San Diego, CA), 1991, pp. 235-276.
Katoh, T., Takahashi, K., DeBoer, D.K., Serhan, C.N. & Badr, K.F.,Am. J. Physiol. 263, 1992, F436-442.
Marriott, J.B., Westby, M. & Dalgleish, A.G.,Drug Discovery Today2, 1997, pp. 273-282.
Abstract No. 252676t “Neutrophil-Mediated Changes in Vascular Permeability are Inhibited by Topical Applicaton of Aspirin-Triggered 15-epi-Lipoxin A4and Novel Lipoxin B4Stable Analogs”,Chemical Abstracts, vol. 128, No. 21, p. 41, col. R, 1998.
Hennekens, C.H.,N. Engl. J. Med. 336, 1997, pp. 973-979.
Chavis, C., Vachier, I., Chanez, P., Bousquet, J. & Godard, P.,J. Exp. Med. 183, pp. 1633-1643, 1996.
Carr Deborah D
Fairman, Esq. Colin L.
Fulbright & Jaworski LLP
Rothenberger, Esq. Scott D.
The Brigham and Women's Hospital, Inc.
LandOfFree
Prevention of neutrophil recruitment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of neutrophil recruitment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of neutrophil recruitment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132256